#United States #Menlo Park #Octapharma #Abram Scientific #CoagCare

Abram Scientific Secures $11.75M Series A Funding

Abram Scientific, a pioneering medical device company based in Menlo Park, California, has made headlines with its recent achievement of securing $11.75 million in Series A funding. This significant financing round was led by Octapharma AG, a global leader in the pharmaceutical industry known for its innovative approaches. Existing and new investors associated with the University of Colorado Anschutz also participated, indicating strong institutional support for Abram's mission.

The infusion of capital will primarily be directed towards the advancement of Abram Scientific's proprietary diagnostic platform, CoagCare™. This revolutionary tool aims to enhance patient care for individuals suffering from bleeding disorders, particularly in critical care settings. The funds will aid in refining the CoagCare system, facilitating its journey towards achieving necessary clinical milestones and obtaining FDA 510(k) clearance for marketing in the United States.

The CoagCare™ system stands out as a next-generation diagnostic solution designed to rapidly assess blood clotting disorders. Utilizing a point-of-care (POC) meter and a single-use diagnostic test card, it promises to deliver real-time hemostasis information efficiently. This technology employs proprietary methods to quickly measure blood's viscoelasticity and density, capturing the intricate details of the blood coagulation process in under ten minutes. This rapid analysis can significantly improve outcomes for patients undergoing trauma or surgical procedures by promptly informing healthcare providers about the necessary interventions.

Unlike existing diagnostic platforms such as thromboelastography (TEG®) and thromboelastometry (ROTEM®), which can take 30 to 60 minutes for complete assessments, CoagCare™ transforms care delivery. Its ability to produce immediate results from a single drop of blood positions it as a crucial instrument in emergency situations where every second matters. This capability makes CoagCare™ particularly useful in environments lacking stable, laboratory-grade conditions, like ambulances and MEDVAC helicopters.

Abhishek Ramkumar, CEO and founder of Abram Scientific, emphasized the company’s mission: "To enable CoagCare to help adjudicate life-saving therapies and transfusions, ensuring that the right treatment is delivered at the right moment and in the correct dosage." Collaborating with Octapharma and the University of Colorado not only provides necessary funding but also strategic insights to expedite the development process.

Octapharma has a strong reputation for improving healthcare outcomes, focusing on critical care therapies that enhance patient care. Their investment in Abram Scientific marks their entry into the diagnostics sector, demonstrating their commitment to addressing unmet clinical needs in hematology and critical care.

Flemming Nielsen, President of Octapharma USA, expressed excitement about this partnership, recognizing the unique approach Abram Scientific takes toward patient care. He stated, "Abram has a unique approach with real potential to reshape patient outcomes, ensuring the right intervention, at the right time, in the right amount. This represents an important step forward in patient care and can help shape clinical guidelines nationally and globally."

Highlighting the urgency behind their mission, Dr. Vik Bebarta, an endowed chair in emergency medicine at the University of Colorado Anschutz, underscored the significance of the CoagCare system in critical environments. He remarked, "Uncontrolled hemorrhage remains one of the leading—and most preventable—causes of early trauma death. We are excited to partner with Abram Scientific to develop CoagCare to give surgeons and emergency physicians the critical information they need sooner to guide life-saving therapy decisions."

Founded by Dr. Abhishek Ramkumar, Abram Scientific operates with a strong intellectual property foundation, holding numerous patents for its CoagCare technology. The platform's effectiveness and potential to change current clinical practices make it a compelling focal point in the ongoing evolution of medical diagnostics.

This funding round serves not only as a financial boost but as a pivotal moment for Abram Scientific, positioning the CoagCare system to become an essential tool in the future of emergency medicine and trauma care. The collaboration with established players in the field reflects a strong vote of confidence in the efficacy and necessity of their innovative diagnostic approach.

Conclusion

As the healthcare landscape continues to evolve, tools like CoagCare™ offer hope for dramatically improving patient outcomes in emergencies. With robust investments and partnerships, Abram Scientific is set to make a lasting impact on how we approach coagulation diagnostics and critical patient care.